BeOne Medicines (NASDAQ:ONC) COO Xiaobin Wu Sells 280 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu sold 280 shares of BeOne Medicines stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $380.00, for a total transaction of $106,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xiaobin Wu also recently made the following trade(s):

• On Tuesday, June 23rd, Xiaobin Wu sold 1,292 shares of BeOne Medicines stock. The stock was sold at an average price of $276.26, for a total transaction of $356,927.92.
• On Tuesday, June 16th, Xiaobin Wu sold 1,357 shares of BeOne Medicines stock. The stock was sold at an average price of $266.76, for a total transaction of $361,993.32.
• On Thursday, June 11th, Xiaobin Wu sold 626 shares of BeOne Medicines stock. The shares were sold at an average price of $261.20, for a total transaction of $163,511.20.
• On Monday, June 8th, Xiaobin Wu sold 1,484 shares of BeOne Medicines stock. The stock was sold at an average price of $269.37, for a total transaction of $399,745.08.

BeOne Medicines Stock Down 0.9%

Shares of BeOne Medicines stock traded down $3.31 during trading hours on Thursday, reaching $372.49. 225,066 shares of the company were exchanged, compared to its average volume of 293,355. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $253.95 and a 1 year high of $385.22. The firm has a market cap of $40.89 billion, a PE ratio of 65.58 and a beta of 0.49. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.06 and a current ratio of 3.40. The stock’s fifty day moving average is $321.55 and its 200 day moving average is $310.79.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.65. The company had revenue of $1.71 billion for the quarter, compared to the consensus estimate of $1.66 billion. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. As a group, equities research analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 8.81 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ONC. Mariner LLC raised its position in BeOne Medicines by 3.8% in the 4th quarter. Mariner LLC now owns 883 shares of the company’s stock valued at $269,000 after purchasing an additional 32 shares during the last quarter. Farther Finance Advisors LLC grew its position in BeOne Medicines by 21.8% during the 4th quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock worth $66,000 after purchasing an additional 39 shares during the last quarter. CWM LLC grew its position in BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after purchasing an additional 39 shares during the last quarter. Steadtrust LLC increased its stake in BeOne Medicines by 3.7% in the second quarter. Steadtrust LLC now owns 1,400 shares of the company’s stock valued at $399,000 after purchasing an additional 50 shares during the period. Finally, Benjamin Edwards Inc. increased its stake in BeOne Medicines by 8.0% in the fourth quarter. Benjamin Edwards Inc. now owns 690 shares of the company’s stock valued at $210,000 after purchasing an additional 51 shares during the period. 48.55% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on ONC. Guggenheim raised their target price on shares of BeOne Medicines from $420.00 to $430.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a report on Friday, July 17th. Truist Financial increased their price objective on shares of BeOne Medicines from $416.00 to $418.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Citigroup restated an “outperform” rating on shares of BeOne Medicines in a report on Thursday, August 6th. Finally, Zacks Research raised shares of BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 7th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $402.14.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.